+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2025

  • ID: 5094114
  • Report
  • June 2020
  • Region: Global
  • 217 Pages
  • BIS Research

Enquire about COVID-19 updates for this product.

Enquire Now
Global Infectious Disease Rapid Diagnostic Testing Market to Reach $2,853.2 Million by 2025

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMérieux S.A.
  • CTK Biotech
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Luminex Corporation
  • MORE

Market Report Coverage - Infectious Disease Rapid Diagnostic Testing

Market Segmentation

  • Product - Infectious Disease Diagnostics Assays and Platforms
  • Technology - Real-Time PCR, Isothermal Nucleic Acid Amplification Technology (INAAT), Lateral Flow Immunoassay, Enzyme Immunoassay, and Others
  • Disease - Bacterial, Viral, and Others
  • Application - Respiratory Infection, Gastro-intestinal Infection, Central Nervous System Infection, sexually transmitted infections, Hospital Acquired Infections and Other Infections
  • End User - Hospital, Clinics, Diagnostic Centers, and Other End Users

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Russia, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Taiwan, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Middle East
  • Africa
  • Rest-of-the-World

Growth Drivers

  • Rising Incidence of Frequent Pandemics such as COVID-19 Infectious Disease Inciting the Development of Rapid Diagnostic Assays
  • Significant Innovation Resulting in Market Pull
  • Shift from Centralized to Decentralized Laboratories
  • Significant External Funding for Executing R&D Exercises

Market Challenges

  • Lack of Standard Regulatory Processes
  • Shortage of Skilled Professionals and Trained Lab Technicians
  • Less Efficiency of Rapid Diagnostic Testing as Compared with Laboratory Testing

Market Opportunities

  • Development of Infectious Disease Diagnostic Assays for Various Clinical Areas
  • Massive Scope for Adoption of Infectious Disease Rapid Diagnostic Testing in Emerging Nations

Key Companies Profiled

Abbott Laboratories, F. Hoffman-La Roche Ltd, Danaher Corporation, Luminex Corporation, BGI Group, bioMérieux S.A., DiaSorin S.p.A, Hologic, Inc., Mesa Biotech, Quidel Corporation, Thermo Fisher Scientific Inc., GenMark Diagnostics, CTK Biotech, Becton, Dickinson and Company, and Cellex Inc.

Key Questions Answered:
What are the major market drivers, challenges, and opportunities in the global infectious disease rapid diagnostics testing market?
What are the underlying structures resulting in the emerging trends within the infectious disease diagnostic assays and systems?
What was the market value of the leading segments of the global infectious disease rapid diagnostics testing market in 2019?
What are the influencing factors that may affect the market share of the key players?
How is the industry expected to evolve during the forecast period 2020-2025?
What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
What is the current market share of each of the companies in the global infectious disease rapid diagnostics testing market and what are expected to be their contributions in 2025?
What is the growth potential of infectious disease diagnostics in each region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa and Rest-of-the-World?
What are the key regulatory implications in developed and developing regions for infectious disease diagnostics?
What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2020-2025?
What key strategies have been incorporated by the leading players for furthering the growth of the infectious disease industry?
How is a pandemic such as COVID-19 expected to impact the development of rapid diagnostic for infectious disease testing?

Market Overview

Our healthcare experts have found the infectious disease industry to be one of the most rapidly evolving markets. The global market for infectious disease rapid diagnostic testing is predicted to grow at a CAGR of 12.36% over the forecast period of 2020-2025. The market is driven by certain factors, which include the rising incidence of frequent pandemics such as COVID-19, infectious diseases inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, a shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.

The market is favored by the development of rapid diagnostics assays for several clinical areas such as respiratory infections, central nervous system infections, sexually transmitted infections, among others. Recent infectious disease outbreaks such as Zika, Ebola, and COVID- 19 have furthered the growth of the market.

Furthermore, several diagnostic companies are focusing on the development of rapid diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing a diagnosis of infectious disease at the point of care.

Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of rapid diagnostics providing accurate results at a shorter turn-around time. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as F. Hoffman-La Roche Ltd, GenMark Diagnostics Inc., and Bio-Rad Laboratories, among others, have launched diagnostics assays for COVID-19, such as cobas SARS-CoV-2 Test, ePlex SARS-CoV-2 Test, and Fast Track Diagnostics (FTD) SARS-CoV-2 Assay respectively, to compete with ABBOTT REALTIME SARS-COV-2 ASSAY market dominance.

On the basis of region, North America holds the largest share of infectious disease rapid diagnostic testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Enterprise License customers will receive an Excel spreadsheet containing additional data.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMérieux S.A.
  • CTK Biotech
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Luminex Corporation
  • MORE

Executive Summary

1 Product Definition
1.1 Definition by Products
1.1.1 Platforms
1.1.2 Assays
1.2 Inclusion and Exclusion

2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model

4 Market Overview
4.1 Definitions
4.1.1 Market Definition
4.1.2 Definition by Products
4.1.2.1 Platforms
4.1.2.2 Assays
4.2 Infectious Disease Rapid Diagnostic Technologies
4.3 Situation Analysis: Pre-COVID Vs. Post-COVID
4.4 Impact of COVID-19 on Infectious Disease Rapid Diagnostic Testing
4.4.1 Impact of COVID-19 on Different Countries
4.5 Market Size and Growth Potential, $Million, 2019-2025
4.5.1 Overview
4.5.2 Most Promising Countries in the Infectious Disease Rapid Diagnostic Testing Market
4.5.2.1 U.S.
4.5.2.2 Italy
4.5.2.3 China
4.5.2.4 India
4.5.2.5 Brazil
4.5.2.6 Kingdom of Saudi Arabia (K.S.A.)
4.5.2.7 Democratic Republic of Congo

5 Market Dynamics
5.1 Overview
5.2 Impact Analysis
5.3 Drivers
5.3.1 Rising Incidence of Frequent Pandemics, such as COVID-19 Infectious Disease, Inciting the Development of Rapid Diagnostic Assays
5.3.2 Significant Innovation Resulting in Market Pull
5.3.3 Shift from Centralized to Decentralized Laboratories
5.3.4 Significant External Funding for Executing R&D Exercises
5.4 Restraints
5.4.1 Lack of Standard Regulatory Processes
5.4.2 Shortage of Skilled Professionals and Trained Lab-Technicians
5.4.3 Less Efficiency of Rapid Diagnostic Testing as Compared with that of Laboratory Testing
5.5 Opportunities
5.5.1 Development of Infectious Disease Diagnostic Assays for Various Clinical Areas

6 Global Infectious Disease Rapid Testing Market (by Product), $Million, 2019-2025
6.1 Overview
6.2 Assays
6.3 Platforms

7 Global Infectious Disease Rapid Testing Market (by Technology), $Million, 2019-2025
7.1 Overview
7.2 Real-Time PCR (q-PCR)
7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.4 Lateral Flow Immunoassay (LFIA)
7.5 Enzyme Immunoassay (EIA)
7.6 Others

8 Global Infectious Disease Rapid Testing Market (by Application), $Million, 2019-2025
8.1 Overview
8.2 Respiratory Infection
8.3 Gastro-Intestinal Infection
8.4 Center Nervous System Infection
8.5 Hospital Acquired Infection
8.6 Sexually Transmitted Infections
8.7 Others

9 Global Infectious Disease Rapid Testing Market (by Disease), $Million, 2019-2025
9.1 Overview
9.2 Bacterial Infection
9.2.1 Hospital Acquired Infections
9.2.2 Tuberculosis
9.2.3 CT/NG
9.2.4 Others
9.3 Viral Infections
9.3.1 Influenza Virus
9.3.2 Hepatitis
9.3.3 HIV-AIDS
9.3.4 HPV
9.3.5 Others
9.4 Other Infections

10 Emerging Companies in the Global Infectious Disease Rapid Diagnostic Testing Market
10.1 XCR Diagnostics, Inc.
10.2 Co-Diagnostics Inc.
10.3 Inflammatix, Inc.
10.4 DNA Electronics
10.5 Mylab Discovery Solutions Pvt. Ltd.
10.6 CerTest BIOTEC S.L.

11 Global Infectious Disease Rapid Diagnostic Testing Market (by Region)
11.1 Overview
11.2 North America
11.2.1 U.S
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Russia
11.3.7 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Taiwan
11.4.5 South Korea
11.4.6 Singapore
11.4.7 Australia
11.4.8 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Middle East
11.7 Africa
11.8 Rest-of-the-World (RoW)

12 Global Infectious Disease Rapid Diagnostic Testing Market (by End User)
12.1 Overview
12.2 Hospitals
12.3 Clinics
12.4 Diagnostic Centers
12.5 Other End Users

13 Competitive Landscape
13.1 Key Strategies and Developments
13.1.1 Product Approvals
13.1.2 Product Launches and Upgradations
13.1.3 Synergistic Activities
13.1.4 Funding and Expansion
13.1.5 Mergers and Acquisitions
13.2 Industry Trends
13.3 Market Share Analysis (by Company), 2019
13.4 Growth Share Analysis (Opportunity Mapping)
13.4.1 By Company
13.4.2 By Application
13.4.3 By Technology

14 Company Profiles
14.1 Overview
14.2 Abbott Laboratories
14.2.1 Company Overview
14.2.2 Analyst Insights
14.3 F. Hoffmann-La Roche Ltd
14.3.1 Company Overview
14.3.2 Analyst Insights
14.4 Danaher Corporation
14.4.1 Company Overview
14.4.2 Analyst Insights
14.5 Luminex Corporation
14.5.1 Company Overview
14.5.2 Analyst Insights
14.6 BGI Group
14.6.1 Company Overview
14.6.2 Analyst Insights
14.7 bioMérieux S.A.
14.7.1 Company Overview
14.7.2 Analyst Insights
14.8 DiaSorin S.p.A
14.8.1 Company Overview
14.8.2 Analyst Insights
14.9 Hologic, Inc.
14.9.1 Company Overview
14.9.2 Analyst Insights
14.10 Mesa Biotech
14.10.1 Company Overview
14.10.2 Analyst Insights
14.11 Quidel Corporation
14.11.1 Company Overview
14.11.2 Analyst Insights
14.12 Thermo Fisher Scientific Inc.
14.12.1 Company Overview
14.12.2 Analyst Insights
14.13 GenMark Diagnostics
14.13.1 Company Overview
14.13.2 Analyst Insights
14.14 CTK Biotech
14.14.1 Company Overview
14.14.2 Analyst Insights
14.15 Becton, Dickinson and Company
14.15.1 Company Overview
14.15.2 Analyst Insights
14.16 Cellex
14.16.1 Company Overview
14.16.2 Analyst Insights

List of Tables
Table 5.1: Impact Analysis of Market Drivers
Table 5.2: Impact Analysis of Market Restraints
Table 6.1: Key Rapid Diagnostic Assays Offered for Infectious Disease
Table 6.2: Key Platforms Offered for Infectious Disease
Table 7.1: Key Products Offered Based on RT-PCR
Table 7.2: Key Products Offered Based on INAAT
Table 7.3: Key Products Offered Based on LFIA
Table 7.4: Key Products Offered Based on EIA
Table 7.5: Key Products Offered Based on Other Technologies
Table 8.1: Key Products Offered for COVID-19 Diagnosis
Table 8.2: Key Products Offered for Respiratory Infection Diagnosis
Table 8.3: Key Products Offered for Gastro-Intestinal Infection
Table 8.4: Key Products Offered for Center Nervous System Infection
Table 8.5: Key Products Offered for Hospital-Acquired Infections
Table 8.6: Key Products Offered for Sexually Transmitted Infections
Table 8.7: Key Products Offered for Other Applications

List of Figures
Figure 1: Number of COVID-19 Cases in Severely Affected Countries, as of April 8, 2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Infectious Disease Rapid Diagnostic Testing Market
Figure 3: Global Infectious Disease Rapid Diagnostic Testing Market (by Product), 2019 Vs. 2025, $Million
Figure 4: Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019 Vs. 2025, $Million
Figure 5: Global Infectious Disease Rapid Diagnostic Testing Market (by Disease Pathogen), 2019 Vs. 2025, $Million
Figure 6: Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019 Vs. 2025, $Million
Figure 7: Global Infectious Disease Rapid Diagnostic Testing Market (by End User), 2019 Vs. 2025, $Million
Figure 8: Global Infectious Disease Rapid Diagnostic Testing Market Snapshot
Figure 2.1: Global Infectious Disease Rapid Diagnostic Testing Market Segmentation
Figure 4.1: Comparison Between Commercially Available Infectious Disease RDT Products Vs. Laboratory Testing
Figure 4.2: Global Infectious Disease Rapid Diagnostic Market (by Infectious Disease), Pre-COVID-19 Vs. Post-COVID-19
Figure 4.3: Global Infectious Disease Rapid Diagnostic Testing Market, $Million, 2019-2025
Figure 4.4: Major Factors Considered
Figure 5.1: New Cases of Respiratory and Enteric Infections, Globally, 2012-2017
Figure 5.2: Time of Infectious Disease Pandemics
Figure 6.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Product), 2019-2025
Figure 6.2: Global Infectious Disease Rapid Diagnostic Market (by Assays), 2019-2025
Figure 6.3: Global Infectious Disease Rapid Diagnostic Market (Platforms), 2019-2025
Figure 7.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019-2025
Figure 7.2: Global Infectious Disease Rapid Diagnostic Market (RT-PCR), 2019-2025
Figure 7.3: Global Infectious Disease Rapid Diagnostic Market (by INAAT), 2019-2025
Figure 7.4: Global Infectious Disease Rapid Diagnostic Market (LFIA), 2019-2025
Figure 7.5: Global Infectious Disease Rapid Diagnostic Market (EIA), 2019-2025
Figure 7.6: Global Infectious Disease Rapid Diagnostic Market (Others), 2019-2025
Figure 8.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019-2025
Figure 8.2: Global Infectious Disease Rapid Diagnostic Market (Respiratory Infection), 2019-2025
Figure 8.3: Global Infectious Disease Rapid Diagnostic Market (Gastro-Intestinal Infection), 2019-2025
Figure 8.4: Global Infectious Disease Rapid Diagnostic Market (Center Nervous System Infection), 2019-2025
Figure 8.5: Global Infectious Disease Rapid Diagnostic Market (Hospital-Acquired Infection), 2019-2025
Figure 8.6: Global Infectious Disease Rapid Diagnostic Market (Sexually Transmitted Infections), 2019-2025
Figure 8.7: Global Infectious Disease Rapid Diagnostic Market (Other Applications), 2019-2025
Figure 9.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Disease), 2019 and 2025
Figure 9.2: Global Infectious Disease Rapid Diagnostic Market (by Bacterial Infection), 2019-2025
Figure 9.3: Global Infectious Disease Rapid Diagnostic Market for Hospital Acquired Infection, 2019-2025
Figure 9.4: Global Infectious Disease Rapid Diagnostic Market for Tuberculosis, 2019-2025
Figure 9.5: Global Infectious Disease Rapid Diagnostic Market for CT/NG, 2019-2025
Figure 9.6: Global Infectious Disease Rapid Diagnostic Market for Other Bacterial Infections, 2019-2025
Figure 9.7: Global Infectious Disease Rapid Diagnostic Market (by Viral Infection), 2019-2025
Figure 9.8: Global Infectious Disease Rapid Diagnostic Market Y-o-Y (by Viral Infection), 2019-2025
Figure 9.9: Global Infectious Disease Rapid Diagnostic Market for Influenza, 2019-2025
Figure 9.10: Global Infectious Disease Rapid Diagnostic Market for Hepatitis, 2019-2025
Figure 9.11: Global Infectious Disease Rapid Diagnostic Market for HIV-AIDS, 2019-2025
Figure 9.12: Global Infectious Disease Rapid Diagnostic Market for HPV, 2019-2025
Figure 9.13: Global Infectious Disease Rapid Diagnostic Market for Other Viral Infections, 2019-2025
Figure 9.14: Global Infectious Disease Rapid Diagnostic Market for Other Infections, 2019-2025
Figure 11.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Region), 2020 and 2025
Figure 11.2: Global Infectious Disease Rapid Diagnostic Testing Market (by Region), 2019-2025
Figure 11.3: Number of Confirmed COVID-19 Cases in Severely Affected Countries, as of April 8, 2020
Figure 11.4: Global Infectious Disease Rapid Diagnostic Testing Market Share (by Region), 2019 and 2025
Figure 11.5: North America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.6: North America Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
Figure 11.7: North America: Market Dynamics
Figure 11.8: U.S. Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.9: Month-Wise COVID-19 Cases, the U.S., as of April 8, 2020
Figure 11.10: Canada Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.11: Month-Wise COVID-19 Cases, Canada, as of April 8, 2020
Figure 11.12: Europe Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.13: Europe: Market Dynamics
Figure 11.14: Europe Rapid Infectious Disease Diagnostic Testing Market (by Country), 2019-2025
Figure 11.15: Germany Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.16: Month-Wise COVID-19 Cases, Germany, as of April 8, 2020
Figure 11.17: U.K. Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.18: Month-Wise COVID-19 Cases, the U.K., as of April 8, 2020
Figure 11.19: France Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.20: Month-Wise COVID-19 Cases, France, as of April 8, 2020
Figure 11.21: Italy Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.22: Month-Wise COVID-19 Cases, Italy, as of April 8, 2020
Figure 11.23: Spain Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.24: Month-Wide COVID-19 Cases, Spain, as of April 8, 2020
Figure 11.25: Russia Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.26: Month-Wise COVID-19 Cases, Russia, as of April 8, 2020
Figure 11.27: Rest-of-Europe Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.28: APAC Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.29: APAC: Market Dynamics
Figure 11.30: APAC Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
Figure 11.31: China Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.32: Month-Wise COVID-19 Cases, China, as of April 8, 2020
Figure 11.33: Japan Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.34: Month-Wise COVID-19 Cases, Japan, as of April 8, 2020
Figure 11.35: India Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.36: Month-Wise COVID-19 Cases, India, as of April 8, 2020
Figure 11.37: Taiwan Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.38: Month-Wise COVID-19 Cases, Taiwan, as of April 8, 2020
Figure 11.39: South Korea Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.40: Month-Wise COVID-19 Cases, South Korea, as of April 8, 2020
Figure 11.41: Singapore Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.42: Month-Wise COVID-19 Cases, Singapore, as of April 8, 2020
Figure 11.43: Australia Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.44: Month-Wise COVID-19 Cases, Australia, as of April 8, 2020
Figure 11.45: Rest-of-APAC Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.46: Latin America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.47: Latin America: Market Dynamics
Figure 11.48: Latin America Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
Figure 11.49: Brazil Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.50: Month-Wise COVID-19 Cases, Brazil, as of April 8, 2020
Figure 11.51: Mexico Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.52: Month-Wise COVID-19 Cases, Australia, as of April 8, 2020
Figure 11.53: Rest-of-Latin America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.54: Middle East Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.55: Month-Wise COVID-19 Cases, KSA & UAE, as of April 8, 2020
Figure 11.56: Africa Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 11.57: Month-Wise COVID-19 Cases, Egypt, Ethiopia, Nigeria, and Democratic Republic of Congo, as of April 8, 2020
Figure 11.58: RoW Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
Figure 12.1: Global Infectious Disease Rapid Diagnostic Market (by End User)
Figure 12.2: Global Infectious Disease Rapid Diagnostic Testing Market (by End User), 2019-2025
Figure 12.3: Global Infectious Disease Rapid Diagnostic Testing Market (by Hospitals), 2019-2025
Figure 12.4: Global Infectious Disease Rapid Diagnostic Testing Market (by Clinics), 2019-2025
Figure 12.5: Global Infectious Disease Rapid Diagnostic Testing Market (by Diagnostic Centers), 2019-2025
Figure 12.6: Global Infectious Disease Rapid Diagnostic Testing Market (by Other End Users), 2019-2025
Figure 13.1: Share of Key Developments and Strategies, 2016–2020
Figure 13.2: Product Approval Share (by Company), 2016 – 2020
Figure 13.3: Product Launch and Upgradation Share (by Company), 2016 –2020
Figure 13.4: Synergistic Activities Share (by Company), 2016 –2020
Figure 13.5: Funding and Expansion Share (by Company), 2016 –2020
Figure 13.6: Mergers and Acquisitions Share (by Company), 2016 –2020
Figure 13.7: Market Share Analysis for the Global Infectious Disease Rapid Diagnostic Testing Market, 2019
Figure 13.8: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Company), 2019
Figure 13.9: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019
Figure 13.10: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Competitive Benchmarking of Abbott Laboratories
Figure 14.3: Competitive Benchmarking of F. Hoffmann-La Roche Ltd
Figure 14.4: Competitive Benchmarking of Danaher Corporation
Figure 14.5: Competitive Benchmarking of Luminex Corporation
Figure 14.6: Competitive Benchmarking of BGI Group
Figure 14.7: Competitive Benchmarking of bioMerieux S.A.
Figure 14.8: Competitive Benchmarking of DiaSorin S.p.A.
Figure 14.9: Competitive Benchmarking of Hologic, Inc.
Figure 14.10: Competitive Benchmarking of Mesa Biotech
Figure 14.11: Competitive Benchmarking of Quidel Corporation
Figure 14.12: Competitive Benchmarking of Thermo Fisher Scientific Inc.
Figure 14.13: Competitive Benchmarking of GenMark Diagnostics
Figure 14.14: Competitive Benchmarking of CTK Biotech
Figure 14.15: Competitive Benchmarking of Becton, Dickinson and Company
Figure 14.16: Competitive Benchmarking of Cellex

Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMérieux S.A.
  • CTK Biotech
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Luminex Corporation
  • MORE

According to the market intelligence report titled “Global Infectious Disease Rapid Diagnostic Testing Market - Analysis and Forecast, 2020-2025”, the global infectious disease rapid diagnostic testing market was valued at $1.249.3 million in 2019 and is anticipated to grow over $2,853.2 million by 2025. The global infectious disease rapid diagnostic testing market is expected to grow at the double-digit compound annual growth rate in the forecast period 2020-2025, aided primarily by the impressive growth in the underlying manufacturing market.

Infectious disease rapid diagnostic testing has emerged as one of the most promising techniques in the field of diagnostics. Infectious disease rapid diagnostic testing is primarily adopted for the diagnosis of various infectious diseases in a restricted clinical environment. The testing primarily relies on the detection of target analyte, offering clinical insights in a stipulated time frame. Such testing is becoming an integral component of the healthcare system across the globe. The adoption of these tests in the healthcare system has aided clinicals in navigating through tough times during the outbreak of highly contagious infections such as Ebola virus disease (EVD), SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), and COVID-19, among others.

“North America is the leading contributor in the infectious disease rapid diagnostic testing market and contributed approximately 42.09% to the global market value in 2019. This region is anticipated to grow at a CAGR of 12.16% during the forecast period 2020-2025 and is expected to continue dominating the global market in 2025. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 13.85% during the forecast period from 2020-2025. The European region also contributed a significant share of 17.96% to the global market in 2019 and is anticipated to grow at a CAGR of 12.05% during the forecast period from 2020-2025.”

Research Highlights:

Infectious disease rapid diagnostic testing market for assays is expected to witness a robust CAGR of 12.44% during the forecast period 2020-2025. However, infectious disease rapid diagnostic testing market for platforms is anticipated to witness the growth of 12.09% during the forecast period, 2020-2025.

Abbott Laboratories is currently the largest shareholder in the global infectious disease rapid diagnostic testing market. This market dominance is attributed to the company’s presence within the market through its dedicated product mix based on its proprietary technologies.

This market intelligence report provides a multi-dimensional view of the global infectious disease rapid diagnostic testing market in terms of market size and growth potential. This research report aims at answering various aspects of the global infectious disease rapid diagnostic testing market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and enhancements, collaborations and agreements, acquisitions and business expansions. The research report provides a comprehensive analysis of the product sales, manufacturers, and trend analysis by segment, market share and growth share analysis by companies. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire infectious disease rapid diagnostic testing market for 2020 and 2025.

This report is a meticulous compilation of research on more than 35 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 20 leading and emerging companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Luminex Corporation, BGI Group, bioMerieux S.A., DiaSorin S.p.A, Hologic, Inc, Mesa Biotech, Quidel Corporation, Thermo Fisher Scientific Inc., GenMark Diagnostics, CTK Biotech, Becton, Dickinson and Company, and Cellex.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global infectious disease rapid diagnostics testing market?
  • What are the underlying structures resulting in the emerging trends within the infectious disease diagnostic assays and systems?
  • What was the market value of the leading segments of the global infectious disease rapid diagnostics testing market in 2019?
  • What are the influencing factors that may affect the market share of the key players?
  • How is the industry expected to evolve during the forecast period 2020-2025?
  • What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
  • What is the current market share of each of the companies in the global infectious disease rapid diagnostics testing market and what are expected to be their contributions in 2025?
  • What is the growth potential of infectious disease diagnostics in each region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa and Rest-of-the-World?
  • What are the key regulatory implications in developed and developing regions for infectious disease diagnostics?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2020-2025?
  • What key strategies have been incorporated by the leading players for furthering the growth of infectious disease industry?
  • How is a pandemic such as COVID-19 expected to impact development of rapid diagnostic for infectious disease testing?
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • BGI Group
  • Becton, Dickinson and Company
  • bioMérieux S.A.
  • CTK Biotech
  • Cellex
  • Danaher Corporation
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics
  • Hologic, Inc.
  • Luminex Corporation
  • Mesa Biotech
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll